The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of helicobacter pylori

Helicobacter

Volumn 15, Issue 3, 2010, Pages 206-213

  Song, Min Jun ^a   Park, Dong Il ^a   Park, Jung Ho ^a   Kim, Hong Joo ^a   Cho, Yong Kyun ^a   Sohn, Chong Il ^a   Jeon, Woo Kyu ^a   Kim, Byung Ik ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Eradication; Helicobacter pylori; Mucoprotective agent; Probiotics; Saccharomyces boulardii

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; ARTEMISIA ASIATICA EXTACT; BIOFLOR 250; CARBON 13; CLARITHROMYCIN; DA 9601; MUCOPROTECTIVE AGENT; OMEPRAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; SACCHAROMYCES BOULARDII EXTRACT; STILLEN; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT; PLANT EXTRACT; UREA;

ADOLESCENT; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTEMISIA; ARTEMISIA ASIATICA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DUODENUM ULCER; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; UREA BREATH TEST; BREATH ANALYSIS; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; ISOLATION AND PURIFICATION; MIDDLE AGED; SACCHAROMYCES; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

HELICOBACTER PYLORI; SACCHAROMYCES BOULARDII;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREATH TESTS; FEMALE; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; PROBIOTICS; PROTON PUMP INHIBITORS; SACCHAROMYCES; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 77952139915     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00751.x     Document Type: Article

References (48)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984 1 : 1311 1311.
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002 347 : 1175 1186.
3. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002 16 (Suppl. 1 3 15.
4. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007 12 : 333 340.
5. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 781. (Pubitemid 46854190)
6. Kim JM, Kim JS, Jung HC, Kim N, Song IS. Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003. Korean J Gastroenterol 2004 44 : 126 135.
7. Woo HY, Park DI, Park H, et al. Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens. Helicobacter 2009 14 : 22 8.
8. Hunt RH. Eradication of Helicobacter pylori infection. Am J Med 1996 100 : 42S 50S.
9. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009 24 : 1587 1600.
10. Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Ruffalo SM, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Int Med 2000 160 : 1285 1291.
11. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 603 609.
12. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007 12 : 31 5.
13. Kim N, Park SH, Seo GS, et al. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. Helicobacter 2008 13 : 542 549.
14. Park SK, Park DI, Choi JS, et al. The effect of probiotics on Helicobacter pylori eradication. Hepatogastroenterology 2007 54 : 2032 2036.
15. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008 13 : 261 268.
16. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007 25 : 155 168.
17. Jonkers D, StockbrÜgger R. Probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther 2007 26 (Suppl 2 133 148.
18. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics -Saccharomyces boulardii. Aliment Pharmacol Ther 2007 26 : 767 778.
19. Czerucka D, Rampal P. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 2002 4 : 733 739.
20. Gill Hs. Probiotics to enhance anti-infective defences in the gastro intestinal tract. Best Pract Res Clin Gastroenterol 2003 17 : 755 773.
21. Oh TY, Ryu BK, Yang JI, et al. Studies on antiulcer effects of DA-9601, an Artemisia herba extract against experimental gastric ulcers and its mechanism. J Appl Pharmacol 1996 4 : 111 121.
22. Lee JJ, Han BG, Kim MN, Chung MH. The inhibitory effect of Eupatilin on Helicobacter pylori-induced release of Leukotriene D4 in the human neutrophils and gastric mucosal cells. Korean J Physiol Pharmacol 1997 1 : 573 580.
23. Bhatia SJ, Kochar N, Abraham P, et al. Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol 1989 27 : 2328 2330.
24. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007 137 : 812S 8S.
25. Franceschi F, Cazzato A, Nista EC, et al. Role of probiotics in patients with Helicobacter pylori infection. Helicobacter 2007 12 : 59 63.
26. Dooley CP, Cohen H, Fitzgibbons PL, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989 321 : 1562 1566.
27. Harris PR, Smythies LE, Smith PD, Dubois A. Inflammatory cytokine mRNA expression during early and persistent Helicobacter pylori infection in nonhuman primates. J Infect Dis 2000 181 : 783 786.
28. Smythies LE, Waites KB, Lindsey JR, Harris PR, Ghiara P, Smith PD. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol 2000 165 : 1022 1029.
29. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006 5 : 197 209.
30. Rudi J, Kuck D, Strand S, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest 1998 102 : 1506 1514.
31. Hojo M, Miwa H, Kikuchi S, Sato N. Do mucosal defensive agents improve the cure rate when used with dual or triple therapy regimens for eradicating Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 193 201.
32. Shibata K, Ito Y, Hongo A, Yasoshima A, Endo T, Ohashi M. Bactericidal activity of a new antiulcer agent, Ecabet Sodium, against Helicobacter pylori under acidic conditions. Antimicrob Agents Chemother 1995 39 : 1295 1299.
33. Hayashi S, Sugiyama T, Amano K, et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother 1998 42 : 1895 1899. (Pubitemid 28363066)
34. Suzuki M, Miura S, Mori M, et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 1994 35 : 1375 1378.
35. Aihara M, Azuma A, Takizawa H, et al. Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 1998 43 (9 Suppl 174S 80S.
36. Bortolotti M, Brunelli F, Sarti P, Mari C, Miglioli M. Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Aliment Pharmacol Ther 1998 12 : 1021 1025.
37. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002 97 : 2744 2749.
38. Gionchetti P, Rizzello F, Campieri M. Probiotics in gastroenterology. Curr Opin Gastroenterol 2002 18 : 235 239.
39. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999 13 (Suppl 3 27 36.
40. Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabol Drug Interact 1997 14 : 55 82.
41. Ishizaki T, Sohn DR, Kobayashi K, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994 16 : 214 215.
42. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996 60 : 661 666.
43. Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, et al. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 2005 61 : 375 379.
44. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004 76 : 201 209.
45. Sapone A, Vaira D, Trespidi S, et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003 98 : 1010 1015.
46. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis 2001 33 : 671 675.
47. Oh JH, Dong MS, Choi MG, et al. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. J Gastroenterol Hepatol 2009 24 : 294 298.
48. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004 20 : 1001 1017.